采用国际生存质量量表评价肺积方治疗非小细胞肺癌患者生存质量

目的 采用国际生存质量量表评价肺积方治疗非小细胞肺癌患者生存质量。方法 将102例非小细胞肺癌患者随机分为两组，联合组（61例）接受肺积方治疗及化疗，对照组（41例）单纯接受化疗，共观察两个疗程。采用EORTC QLQ-C43与FACT-L两种国际生存质量量表作为测定工具，并以传统的临床疗效评价指标作为参照。结果 联合组生存质量各领域包括功能子领域及症状子领域评分治疗后明显改善，对照组则明显下降，两组间比较差异有显著性（P〈0．05）；体能状态ECOG、KPS评分显示相似结果；联合组胃肠道反应及骨髓抑制反应较对照组轻（P〈0．05）；临床缓解率两组比较差异无显著性（P〉0．05）。结论 肺积方具有改善非小细胞肺癌患者生存质量，减轻化疗毒副反应，改善体能状态的作用。

Evaluation on Effect of Feiji Recipe on Quality of Life of Patients with Non-small Cell Lung Cancer by Adopting International Questionnaire of QOL

Objective To evaluate the effect of Feiji Recipe (FJR) on quality of life (QOL) of patients with non-small cell lung cancer (NSCLC). Methods One hundred and two patients with NSCLC were randomly assigned into 2 groups. The 61 patients in the combined treated group were given FJR and chemotherapy and the 41 patients in the control group were treated with chemotherapy alone. They were observed for two treatment courses with QOL estimated by EORTC QLQ-C43 questionnaire and FACT-L questionnaire, the two international questionnaires as the tools for measurement, and referred to the traditional evaluating indexes of clinical efficiency. Results QOL in the combined treated group was improved after treatment with the improvement of scores in all domains, including functional and symptom sub-domain, while it in the control group deprived significantly, showing significant difference between the two groups (P<0.05). Similar results were also shown in the evaluation of physical performance by Eastern Cooperative Oncology Group (ECOG) and Karnovfsky performance scoring. The gastrointestinal reaction and myelo-suppression were slighter in the combined treated group than those in the control group (P<0.05), and no significant difference was shown between the response rate of the two groups (P>0.05). Conclusion FJR can improve QOL of patients with NSCLC, reduce the adverse reaction of chemotherapy, and improve patients' physical performance.